Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech...
Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.
The 2021 Biotech Six Pack, Six Stocks We Expect to Double.
We're still putting the 2021 list together now,...
Short Squeeze Mania.
Citius Pharma (CTXR) Locked and Loaded.
Truly Locked and Loaded. Latest $20 Million Round is Biggest News We've Seen...
Make Hay While the Sun Shines. Up 6,400%.
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary...
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...